Dec 20, 2018 - Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.
Dec 19, 2018 - Jim Cramer and Eli Lilly CEO Dave Ricks speak about competition in the migraine treatment space and how Eli Lilly plans to win out.
Dec 19, 2018 - A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
Dec 18, 2018 - Merck (MRK) gains an EU approval for Keytruda as an adjuvant therapy pertaining to adult patients with advanced melanoma.
Dec 18, 2018 - Teva (TEVA) announces positive top-line data from the phase IIIb study on fremanezumab for the preventive treatment of migraine in adult patients.
Dec 14, 2018 - The big drug stocks are on a strong footing of late. Here are five such picks from the biotech and large-cap pharma space that are expected to do well in 2019 too.
Dec 13, 2018 - IBB is iShares Nasdaq Biotechnology ETF tracking Nasdaq Biotechnology Index.In the last three years, IBB has remained flat and significantly underperformed the S&P 500.For retail investors, we think i
Dec 11, 2018 - Has Celgene Entered Bargain Territory?, Stocks: CELG,GILD,BIIB,AMGN, release date:Dec 11, 2018
Dec 11, 2018 - Ultra-thinly traded nano cap Entera Bio (ENTX) is up 42% premarket on triple normal volume, albeit on turnover of only 8,300 shares, in response to its research collaboration and license agreement wit
Dec 10, 2018 - GILD has announced an interim CEO, a GILD veteran, followed by a heavy hitter, the head of Roche's Pharma division, Daniel O'Day.I think there are aspects to GILD's pipeline strategy and communication